About Us
Dedicated to the discovery
and development of
targeted anti-cancer therapeutics
and development of
targeted anti-cancer therapeutics
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled one of the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline.
IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064)，PARP1 selective inhibitor (IMP1734, in collaboration with Eikon Therapeutics) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’ s preliminary clinical data demonstrated superior tolerability and wider therapeutic window compared with other marketed PARPi. The phase III clinical study of Senaparib for advanced ovarian cancer maintenance treatment following first-line therapy met primary endpoint, with best-in-class efficacy and safety profile, and its NDA has been accepted by the National Medical Products Administration (NMPA). IMPACT Therapeutics presented pivotal phase 3 clinical data for Senaparib as first-line maintenance therapy in advanced ovarian cancer patients and preliminary clinical data for Senaparib in BRCA1/2 mutated recurrent platinum sensitive ovarian cancer at ESMO Congress 2023. IMPACT is conducted phase I/II study of WEE1 inhibitor (IMP7068) globally and presented preliminary clinical data at ESMO Congress 2023. ATR inhibitor (IMP9064) has also been undergoing phase I clinical studies in multiple countries and regions including United States and China and results of monotherapy dose escalation of FIH study was presented at ESMO 2023. PARP1 selective inhibitor IMP1734 has obtained IND clearance from US FDA and China NMPA.
Established and operated by an experienced management team in the pharmaceutical industry globally, the company has established a fully functional discovery and clinical development organization. The company has received investment from recognized venture capital firms such as Lilly Asia Ventures and Decheng Capital.
IMPACT Therapeutics pursues innovation and create new cancer treatments by unlocking the potential of synthetic lethality. With the scientist spirit, we continue to break new ground as we explore the unlimited possibilities of targeted anti-cancer therapy.
IMPACT Therapeutics respects life above all else. Our dedication to protecting life and meeting the needs of patients drives us to overcome challenges, act decisively, and promote the development of innovative drugs. Our commitment to development enables us to improve the quality of life for our patients.
Mission
Vision
Value
Strategy
Dr. Sui Xiong Cai, Chief Executive Officer, joined the company from San Diego, CA with more than 20 years of drug discovery experience. Served as Senior Director of Chemistry at EpiCept, Maxim Pharmaceuticals and Cytovia Inc., Dr. Cai played critical roles in several anticancer projects that have resulted in two drugs in Phase II clinical trials. He is an inventor of more than 90 issued patents and he received his PhD in Organic Chemistry from University of Oregon.
Dr. Ye Edward Tian, EVP & CSO, came from Transtech Pharma in High Point, NC with 20 years of drug discovery experience. Served as Research Fellow and Associate Director, Dr. Tian played critical roles in several drug discovery projects that have advanced to clinical trials. Prior to that, he was a Senior Scientist at Pfizer in Ann Arbor, MI. Dr. Tian received his PhD in Neuroscience and Pharmacology from Michigan State University.
Dr. Chih-Yi Hsieh, MD, owns over ten years’experiences in oncology clinic and global clinical trials. He was the Chief Medical Officer in ASLAN Pharmaceuticals, leading and completing multiple multinational and single-country clinical trials ranging from phase 1 to global pivotal studies. Prior to that, Dr. Hsieh was Medical Advisor at Novartis Oncology and attending physician in the Taoyuan branch, Taipei Veterans General Hospital. Dr. Chih-Yi Hsieh holds an MD degree from the National Yang-Ming University, Taiwan, and specialist qualifications in Internal Medicine, Medical Oncology, Hematology, and in Blood and Marrow Transplantation.
Susie has more than 20 years working experience with solid finance & operation management, investment and financing, strategic management in pharmaceutical and bio-technological industry. Prior to IMPACT, she served as Chief Financial Officer at many companies including dMed and Betta Pharma, where she was responsible for comprehensive financial accounting management, budget, internal control and process optimization, fiscal taxation and financing, business channel management and integration, external merger and acquisition negotiation, as well as Betta's IPO listing in the A-share. Susie graduated from Zhejiang University of Finance and Economics with Bachelor degree of International Taxation and hold MBA from Fudan University.
Dr. Sui Xiong Cai, Chief Executive Officer, joined the company from San Diego, CA with more than 20 years of drug discovery experience. Served as Senior Director of Chemistry at EpiCept, Maxim Pharmaceuticals and Cytovia Inc., Dr. Cai played critical roles in several anticancer projects that have resulted in two drugs in Phase II clinical trials. He is an inventor of more than 90 issued patents and he received his PhD in Organic Chemistry from University of Oregon.
Dr. Ye Edward Tian, EVP & CSO, came from Transtech Pharma in High Point, NC with 20 years of drug discovery experience. Served as Research Fellow and Associate Director, Dr. Tian played critical roles in several drug discovery projects that have advanced to clinical trials. Prior to that, he was a Senior Scientist at Pfizer in Ann Arbor, MI. Dr. Tian received his PhD in Neuroscience and Pharmacology from Michigan State University.
Dr. Chih-Yi Hsieh, MD, owns over ten years’experiences in oncology clinic and global clinical trials. He was the Chief Medical Officer in ASLAN Pharmaceuticals, leading and completing multiple multinational and single-country clinical trials ranging from phase 1 to global pivotal studies. Prior to that, Dr. Hsieh was Medical Advisor at Novartis Oncology and attending physician in the Taoyuan branch, Taipei Veterans General Hospital. Dr. Chih-Yi Hsieh holds an MD degree from the National Yang-Ming University, Taiwan, and specialist qualifications in Internal Medicine, Medical Oncology, Hematology, and in Blood and Marrow Transplantation.
Susie has more than 20 years working experience with solid finance & operation management, investment and financing, strategic management in pharmaceutical and bio-technological industry. Prior to IMPACT, she served as Chief Financial Officer at many companies including dMed and Betta Pharma, where she was responsible for comprehensive financial accounting management, budget, internal control and process optimization, fiscal taxation and financing, business channel management and integration, external merger and acquisition negotiation, as well as Betta's IPO listing in the A-share. Susie graduated from Zhejiang University of Finance and Economics with Bachelor degree of International Taxation and hold MBA from Fudan University.
Ning has over 15 years of working experience in innovative drug research and development management in CMC, pre-clinical, and PPM (portfolio project management). Under her leadership and participation, she completed one of the "13th Five Year Plan National Major New Drug Creation" projects, two Shanghai biopharmaceutical support projects, and other science and technology special funds. Before Impact, she worked for GSK plc (China) R&D Center and Roche R&D (China) Co., Ltd., engaged in medicinal chemistry research. Ms. Ma obtained a Master of Science degree from Zhengzhou University and an EMBA degree from China Europe Business School (CEIBS).
Dr. Cong Xu, MD, PhD, MBA, has over 10-year experiences in pre/clinical research and medical affairs in oncology. He is Principle of Lilly Asia Ventures. Prior to that, he was former Medical Director at Eli Lilly. Dr. Cong Xu led new drug development from strategy to operation across various tumor types including abemaciclib, a CDK4/6 inhibitor. He led investments such as EdiGene, Allist, Dizal, Mirati, Cullinan, ImmuneOnco etc. Dr. Xu obtained his PhD in Clemson University and MBA degree from The University of British Columbia.
